Genetic Deletion of Myostatin From the Heart Prevents Skeletal Muscle Atrophy in Heart Failure | Zendy

Joerg Heineke | Zendy; Mannix AugerMessier | Zendy; Jian Xu | Zendy; Michelle A. Sargent | Zendy; Allen J. York | Zendy; Stephen Welle | Zendy; Jeffery D. Molkentin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Genetic Deletion of Myostatin From the Heart Prevents Skeletal Muscle Atrophy in Heart Failure

Author(s) -

Joerg Heineke,

Mannix AugerMessier,

Jian Xu,

Michelle A. Sargent,

Allen J. York,

Stephen Welle,

Jeffery D. Molkentin

Publication year - 2010

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.109.882068

Subject(s) - medicine , myostatin , heart failure , skeletal muscle , atrophy , cardiology , endocrinology

Cardiac cachexia is characterized by an exaggerated loss of skeletal muscle, weakness, and exercise intolerance, although the cause of these effects remains unknown. Here, we hypothesized that the heart functions as an endocrine organ in promoting systemic cachexia by secreting peptide factors such as myostatin. Myostatin is a cytokine of the transforming growth factor-beta superfamily that is known to control muscle wasting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research